Annexon, Inc. (ANNX)

Annexon is a clinical-stage biotech developing complement biology therapies, with its lead asset ANX005 targeting orphan neurological conditions including Guillain-Barré syndrome and Huntington's disease — indications with high unmet need and potential for accelerated regulatory pathways. The analyst community is nearly unanimously bullish, with 9 of 10 analysts rating the stock a Buy and a consensus price target implying over 119% upside from current levels. The primary risk is binary clinical trial outcomes: without product revenue, the stock is entirely dependent on pipeline readouts to justify its valuation.

• Phase 3 Guillain-Barré syndrome (GBS) trial readout for ANX005, which could serve as a near-term binary catalyst and potential accelerated FDA approval trigger
• Upcoming data updates on ANX005 in Huntington's disease, where positive biomarker or functional endpoints could meaningfully expand the addressable market narrative
• Potential partnership or licensing deal activity driven by the strong complement biology platform, which could provide non-dilutive capital and validate pipeline assets

• Binary clinical risk: a Phase 3 failure in GBS or Huntington's disease could erase the majority of market cap, as the company has no approved products or commercial revenue to provide a floor
• Cash runway and dilution risk: as a pre-revenue company with ongoing R&D burn, additional equity raises are likely, which could dilute existing shareholders — especially pressuring the stock if raised at a discount
• Regulatory and competitive risk: the complement inhibitor space is increasingly crowded, and any setbacks in FDA interactions or competitive trial data from peers could undermine ANNX's differentiation thesis

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →